<?xml version="1.0" encoding="UTF-8"?>

<wo-patent-document lang="fr" status="175" country="OA">
  <wo-bibliographic-data status="BR100 Migrated">
    <classifications-ipcr>
      <classification-ipcr sequence="0001">
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <section>A</section>
        <class>61</class>
        <subclass>P</subclass>
        <main-group>15</main-group>
        <subgroup>00</subgroup>
        <classification-value>A</classification-value>
      </classification-ipcr>
      <classification-ipcr sequence="0002">
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <section>C</section>
        <class>07</class>
        <subclass>C</subclass>
        <main-group>51</main-group>
        <subgroup>00</subgroup>
        <classification-value>A</classification-value>
      </classification-ipcr>
      <classification-ipcr sequence="0003">
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <section>C</section>
        <class>07</class>
        <subclass>D</subclass>
        <main-group>487</main-group>
        <subgroup>04</subgroup>
        <classification-value>A</classification-value>
      </classification-ipcr>
    </classifications-ipcr>
    <application-reference>
      <document-id>
        <country>OA</country>
        <doc-number>1/2005/000352</doc-number>
        <date>20040514</date>
      </document-id>
    </application-reference>
    <priority-claims>
      <priority-claim sequence="0001" kind="national">
        <country>CN</country>
        <doc-number>03142399.X</doc-number>
        <date>20030606</date>
      </priority-claim>
    </priority-claims>
    <parties>
      <applicants>
        <applicant sequence="0001" app-type="applicant" designation="all">
          <addressbook lang="fr">
            <name>TIANJIN NORTH PHARMA SCI-TECH CO., LTD.</name>
            <address>
              <address-1>C35, Third Floor, No. 7, Kaihua Road, Huayuan, Sci-Tech Industry Garden</address-1>
              <country>CN</country>
            </address>
          </addressbook>
          <nationality>
            <country/>
          </nationality>
          <residence>
            <country>CN</country>
          </residence>
        </applicant>
        <applicant sequence="0002" app-type="applicant" designation="all">
          <addressbook lang="fr">
            <name>Tianjin Tasly Group Co., Ltd.</name>
            <address>
              <address-1>No. 1, Liaohe Dong Road, Beichen Hi-Tech Park, Beichen District</address-1>
              <country>CN</country>
            </address>
          </addressbook>
          <nationality>
            <country/>
          </nationality>
          <residence>
            <country>CN</country>
          </residence>
        </applicant>
      </applicants>
      <inventors>
        <inventor sequence="0001">
          <addressbook lang="fr">
            <name>WANG, Yongfeng</name>
            <address>
              <address-1>C35, Third Floor, No. 7, Kaihua Road, Huayuan, Sci-Tech Industry Garden</address-1>
              <country>CN</country>
            </address>
          </addressbook>
        </inventor>
        <inventor sequence="0002">
          <addressbook lang="fr">
            <name>ZHAO, Kejun</name>
            <address>
              <address-1>No. 32, Zhujiang Road, Yantai Economic Development Area</address-1>
              <country>CN</country>
            </address>
          </addressbook>
        </inventor>
      </inventors>
      <agents>
        <agent sequence="0001" rep-type="agent">
          <addressbook lang="fr">
            <name>SCP NICO HALLE &amp; Co. LAW FIRM</name>
            <address>
              <address-1>ADRESSE A COMPLETER</address-1>
              <country>CM</country>
            </address>
          </addressbook>
        </agent>
      </agents>
    </parties>
    <invention-title lang="fr">2-substituted phenyl-5,7-dialkyl-3,7-dihydropyrrole [2,3-d] pyrimidine-4-one derivatives, the preparation and the pharmaceutical use thereof.</invention-title>
    <wo-term-of-grant>
      <date>20140131</date>
      <doc-number>016216</doc-number>
    </wo-term-of-grant>
    <wo-date-of-expiry>20240514</wo-date-of-expiry>
    <pct-or-regional-filing-data>
      <document-id>
        <country>CN</country>
        <doc-number>PCT/CN04/000487</doc-number>
        <date>20040514</date>
      </document-id>
    </pct-or-regional-filing-data>
    <pct-or-regional-publishing-data>
      <document-id>
        <country>IB</country>
        <doc-number>WO/04/108726</doc-number>
        <date>20040906</date>
      </document-id>
    </pct-or-regional-publishing-data>
    <wo-national-office-event national-office-event-type="Filed" doc-number="OA/1/2005/000352" event-name="Filing">
      <wo-national-office-event-date>
        <date>20040514</date>
      </wo-national-office-event-date>
    </wo-national-office-event>
    <wo-national-office-event national-office-event-type="175" event-name="-">
      <wo-national-office-event-date>
        <date>20041206</date>
      </wo-national-office-event-date>
    </wo-national-office-event>
    <wo-national-office-event national-office-event-type="Registered" doc-number="016216" event-name="Registration">
      <wo-national-office-event-date>
        <date>20140131</date>
      </wo-national-office-event-date>
    </wo-national-office-event>
    <wo-national-office-filing-data appl-type="BR Brevet" file-type="1">
      <kind-of-protection>BR Brevet PCT</kind-of-protection>
    </wo-national-office-filing-data>
  </wo-bibliographic-data>
  <abstract lang="fr">
    <p num="0001">The invention relates to the compounds of formula 1, their preparation and the pharmaceutical compositions containing the compounds. The invention also relates to the use of the compounds of formula I in preparing medicines, which can treat sexual dysfunction of animals including human (male and female), especially erectile dysfunction of male and the diseases in which the function of phospholipase 5 (cGMP PDE5) is involved. Formule 1</p>
  </abstract>
</wo-patent-document>
